Gsk (GSK) Total Current Liabilities (2009 - 2026)

Gsk (GSK) has 18 years of Total Current Liabilities data on file, last reported at -$28.9 billion in Q2 2026.

• For the quarter ending Q2 2026, Total Current Liabilities fell 6.28% year-over-year to -$28.9 billion; the trailing twelve-month figure through Jun 2026 stood at -$28.9 billion (down 6.28% YoY), and the FY2025 full-year result was -$28.5 billion, down 2.59% from the prior year.
• Total Current Liabilities was -$28.9 billion for Q2 2026 at Gsk, up from -$30.2 billion in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of -$6.7 billion in Q1 2022 to a low of -$47.6 billion in Q2 2022.
• A 5-year average of -$27.2 billion and a median of -$27.4 billion in 2023 frame the typical range for Total Current Liabilities.
• Across the five-year window, Total Current Liabilities soared 75.88% in 2022 and sank 273.01% in 2023, its largest moves.
• Gsk's Total Current Liabilities stood at -$26.8 billion in 2022, then gained by 2.26% to -$26.1 billion in 2023, then slipped by 6.5% to -$27.8 billion in 2024, then slipped by 2.17% to -$28.5 billion in 2025, then slipped by 1.54% to -$28.9 billion in 2026.
• Per Business Quant data, the three most recent Total Current Liabilities figures were -$28.9 billion in Q2 2026, -$30.2 billion in Q1 2026, and -$28.5 billion in Q4 2025.